NCT04617275: A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- State
- Completed
- Phase
- Phase 2
- People
- 151 taking part
- Started
- 6 Jan 2021
- Primary completion
- 17 Nov 2021
- Arms
- Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM, Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM, Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM, Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM, Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM, Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity
- Results
- Posted on the registry
- 5 Nov 2020: Trial registered
- 6 Jan 2021: Trial started
- 17 Nov 2021: Trial completed
- 8 Dec 2022: Trial results posted